ASCENTAGE (06855.HK): Four Assets Chosen for ASH 2026, APG-5918 Oral

NewTimeSpace News: On 5 November 2026, Ascentage Pharma Group International (stock code: 06855) announced that multiple clinical and preclinical studies have been selected for the 68th American Society of Hematology (ASH) Annual Meeting, covering four assets: olverembatinib (HQP1351), lisaftoclax (APG-2575), the PRC2/EED inhibitor APG-5918 and the BTK degrader APG-3288. The meeting will be held in New Orleans, Louisiana from 12 to 15 December 2026 in a hybrid format.

APG-5918 will disclose clinical data on efficacy and safety in relapsed/refractory T-cell lymphoma (R/R TCL) for the first time as an oral presentation, abstract No. 513. As at 30 July 2026, the first-in-human Phase I study had enrolled 95 patients with advanced malignancies, of whom 67 had R/R TCL and a median of two prior lines of systemic therapy. Among 47 evaluable TCL patients, the objective response rate was 44.7%, including two complete responses and 19 partial responses, with a disease control rate of 74.5%; in the 20 evaluable patients on 600 mg once daily, the ORR was 65.0%, the complete response rate 10.0% and the DCR 95.0%. No dose-limiting toxicity was observed during dose escalation.

Ascentage will also present data from multiple combination studies of olverembatinib and lisaftoclax across myeloid and lymphoid malignancies in adult and paediatric patients. In paediatric R/R Ph+ ALL, olverembatinib plus lisaftoclax achieved an ORR of 90.0% and an MRD negativity rate of 69.2%, with both agents able to penetrate the blood-brain barrier. The Company included the Rule 18A.05 warning that it cannot guarantee APG-5918 and APG-3288 will obtain further approval or be successfully marketed.